Exagen (XGN) Q3 2025: ASP Rises 9% as Volume and Biomarker Innovation Drive Record Revenue

2025-11-04 | By EarningsIQ Research

Exagen’s Q3 delivered record revenue on dual drivers: robust volume gains and sustained average selling price (ASP) expansion, despite reimbursement friction and a direct bill account loss. The company’s differentiated biomarker portfolio and disciplined sales force expansion are fueling clinical adoption and market share, though ASP acceleration remains gradual. Management’s focus on operational leverage and payer engagement positions Exagen for future margin gains, but near-term cash flow positivity hinges on continued execution in reimbursement and commercial productivity.

Summary

• Biomarker Expansion: Novel rheumatoid arthritis assays deepen Exagen’s clinical moat and drive physician engagement.
• Sales Force Productivity: New territory launches and rep stability are translating into higher per-territory revenue and sustained volume growth.
• Margin Focus: Gross margin resilience and disciplined OpEx support a credible path to positive cash flow, contingent on ASP realization.

Performance Analysis

Exagen posted its highest quarterly revenue in company history, propelled by a 15% year-over-year increase in CTD (connective tissue disease) test volumes and a 9% rise in trailing 12-month ASP to $441 per test. The diagnostic business continues to benefit from both higher test adoption and incremental reimbursement, with volume growth outpacing typical Q3 seasonality and October volume setting a multi-year high. The company’s pharma and CRO (contract research organization) segment also contributed materially, generating $780,000 in Q3 and bringing the YTD total to $1.2 million, compared to only $100,000 for the same period last year.

Gross margin held above 58%, supported by cost discipline and favorable per-test COGS (cost of goods sold), even as new biomarker launches increased R&D and operational expense. Operating expenses rose to $13.2 million, reflecting targeted investment in R&D and sales expansion, but adjusted EBITDA loss narrowed nearly 20% year-over-year to $6.1 million for the first nine months. The loss of a major high-ASP direct bill account created a $20 blended ASP headwind, but was offset by broader volume gains and commercial payer conversion. Exagen ended the quarter with $35.7 million in cash and $11 million in receivables, bolstered by opportunistic ATM (at-the-market) share sales.

• Volume Outperformance: Q3 volume growth defied seasonal slowdown, with October setting a recent high as new sales territories ramped faster than historical norms.
• ASP Progression: ASP continues to climb, but at a slower pace than anticipated, as payer denials for new biomarkers and account mix shifts dampen near-term acceleration.
• Pharma Services Upside: The pharma and CRO business is scaling, with a $3.5 million backlog, validating Exagen’s multi-pronged commercial model.

Despite headwinds from payer reimbursement and a direct bill account transition, Exagen’s dual-engine model—volume and ASP—remains intact, with margin and cash flow leverage poised to improve as payer traction builds.

Executive Commentary

Strategic Positioning

1. Biomarker Innovation and Clinical Differentiation

Exagen’s launch of anti-PAD4 assays—its second novel rheumatoid arthritis marker this year—cements its reputation as a leader in autoimmune biomarker innovation. The company now offers serologic profiling that is positive in 85% of RA patients, up from 70% with conventional methods, enabling more precise disease characterization and treatment guidance. These differentiated assays, developed with sub-$3 million investment and rapid payback, are driving clinical engagement and expanding Exagen’s addressable market.

2. Commercial Channel Expansion and Rep Productivity

Sales force expansion remains disciplined, with 45 territories now active, up from 42 last quarter. Recent hires are already among the top growth performers, and per-territory revenue remains near record levels, even as new territories dilute the average temporarily. Management targets a six to nine month ramp for new reps, with profitability and contribution margin thresholds guiding expansion decisions. This measured approach balances growth with profitability as Exagen penetrates new geographies.

3. ASP Leverage and Revenue Cycle Management

ASP expansion is the linchpin for margin and cash flow improvement, but payer denials on new biomarkers and a major account transition are muting near-term gains. Exagen is doubling down on appeals, payer education, and revenue cycle optimization to secure higher reimbursement. While initial denials for new markers are higher than expected, management remains confident in its playbook, citing past success in driving ASP gains through persistent engagement and data-driven advocacy.

4. Pharma Services Diversification

The pharma and CRO business is gaining traction, with Q3 revenue up sharply and a $3.5 million backlog. Exagen’s unique flow cytometry platform and access to diverse patient samples position it as a preferred partner for drug developers seeking speed, quality, and assay validation. While lumpy, this business line offers incremental revenue streams and strategic partnerships that could become more material over time.

5. Margin Resilience and Capital Stewardship

Gross margin stability near 60% reflects cost discipline and operational leverage, even as OpEx rises with R&D and sales investments. Management sees a credible path to mid-60s gross margin via further ASP gains and workflow optimization. The balance sheet is robust, with $45 million in liquidity and access to $50 million in additional credit, providing ample runway to achieve positive free cash flow.

Key Considerations

Exagen’s Q3 underscores the company’s ability to execute on both commercial and operational fronts, while navigating reimbursement headwinds and capitalizing on biomarker-driven differentiation. Investors should weigh the following:

• Biomarker Portfolio as a Competitive Moat: New RA assays are deepening Exagen’s clinical relevance and driving physician adoption, but payer acceptance lags clinical uptake.
• Sales Expansion Discipline: The company’s measured approach to territory additions and focus on rep productivity is supporting profitable growth and rapid market penetration.
• ASP Acceleration Pace: While the long-term path to $500-plus ASP remains intact, near-term gains are slower due to payer denials and account mix shifts. The appeals process and payer engagement are critical levers.
• Pharma Services as an Emerging Growth Driver: With a growing backlog and differentiated capabilities, pharma and CRO partnerships could become a more meaningful revenue contributor in 2026 and beyond.
• Margin and Cash Flow Trajectory: Gross margin resilience and disciplined OpEx underpin a credible path to profitability, but achieving sustained cash flow positivity depends on ASP realization and continued volume growth.

Risks

Payer pushback on new biomarker reimbursement is resulting in higher-than-expected denials, slowing ASP momentum and delaying cash flow breakeven. The loss of a major high-ASP direct bill account underscores the volatility of client-billed revenue, while commercial payer conversion introduces near-term ASP headwinds. Operational execution in territory expansion and pharma services ramp remains crucial, as does maintaining clinical differentiation amid increasing competition in autoimmune diagnostics.

Forward Outlook

For Q4 2025, Exagen expects:

• Revenue in the $65 to $70 million range for the full year, with cash flow positivity possible at the high end but likely deferred to 2026 due to ASP timing.
• Gross margin to remain near 60%, with upside as ASP improves and COGS optimization continues.

Management highlighted several factors that will shape Q4 and 2026:

• Continued ASP expansion through payer appeals and revenue cycle management, though gains will be gradual.
• Volume growth sustained by new territory ramp and clinical adoption of novel biomarkers.
• Pharma services backlog conversion and further contract wins as a source of incremental growth.

Takeaways

• Dual Engine Growth: Exagen’s top-line is being driven by both volume and ASP, with biomarker innovation reinforcing clinical and commercial momentum.
• Margin and Cash Flow Leverage: Operational discipline and cost control underpin gross margin stability, but ASP realization is the key swing factor for profitability.
• Payer Engagement as a Critical Lever: Investors should monitor progress in payer acceptance for new markers and the pace of ASP expansion, as these will determine the timing of free cash flow inflection.

Conclusion

Exagen’s Q3 results reinforce its differentiated position in autoimmune diagnostics, with record revenue, resilient margins, and a growing pharma services pipeline. While reimbursement friction tempers near-term ASP gains, the company’s strategic focus on innovation, disciplined commercial execution, and operational leverage positions it for durable growth and eventual profitability.

Industry Read-Through

Exagen’s experience highlights the growing importance of biomarker innovation and clinical differentiation in specialty diagnostics, as payers increasingly scrutinize reimbursement for new assays. The company’s dual-engine model—balancing volume growth with ASP expansion—offers a template for others navigating the shift from legacy to value-based diagnostics. The pharma services ramp signals a broader trend of diagnostics companies leveraging platform capabilities for diversified revenue streams, while the volatility in direct bill accounts underscores the need for balanced payer exposure. Investors in autoimmune and specialty diagnostics should watch ASP realization, payer engagement, and margin trajectory as leading indicators of sector health.

XGN Healthcare Diagnostics Biomarkers Reimbursement Pharma services Salesforce Margin